Sector News

Endo CEO touts ‘exciting’ $2.2B bid for Auxilium

September 17, 2014
Life sciences
Endo’s got a deal for Auxilium Pharmaceuticals in mind. CEO Rajiv De Silva thinks it could be a home run, and analysts seem to agree. Auxilium, however, needs some time to think it over, and it’s swallowed a poison pill to make sure it gets just that.
 
Chesterbrook, PA-based Auxilium took up the defense plan Wednesday after receiving Endo’s $2.2 billion cash-and-stock offer, which amounts to a 31% premium on its Tuesday closing price. The poison pill will provide its board with “sufficient time to make informed judgments,” the company said
 
Endo, on the other hand, is “ready to engage immediately with Auxilium, complete our confirmatory diligence, negotiate a definitive agreement and complete this exciting transaction,” De Silva said in a statement. And the way Sterne Agee analyst Shibani Malhotra sees it, it’s no wonder: A deal could provide $0.39 (9%) EPS accretion in 2015 and $0.83 (17%) accretion in 2016. And it comes with the potential for tax synergies to increase those figures down the line, he wrote in a note to clients.
 
Thing is, Auxilium already has a deal of its own in the works for Canadian eye-drug maker QLT–and De Silva has suggested it’ll be one or the other. “Our offer is for Auxilium only,” he said on a Tuesday conference call, as quoted by Reuters. “We would leave it up to Auxilium’s management and its board to come to its own conclusions on how they view our transaction versus the transaction with QLT.”
 
But with portfolios Endo called “highly complementary,” the Malvern, PA-based pharma likes its chances. Auxilium’s 12 FDA-approved products–including Xiaflex, which treats curvature of the penis–would fit right in with its own men’s health and pain offerings, it figures. And it could pile product and location synergies onto the $75 million in cost savings it anticipates squeezing out of a merged company’s operating expenses.
 
As such, Canaccord Genuity analyst Corey Davis, for one, thinks Endo will ultimately prevail in making Auxilium its latest conquest in a string of recent deals. “We think the deal has an uber-high probability of being consummated,” he wrote in a note to clients. “Although Endo was light on number-detail, it would obviously be accretive and is a great first step in the right direction of buying things to maximize [Endo’s] terminal multiple.”
 
By Carly Helfand
 

comments closed

Related News

February 17, 2024

GSK concludes Aiolos Bio acquisition for $1.4bn

Life sciences

The agreement, signed last month, includes an upfront payment of $1bn and $400m in regulatory milestone payments. The acquisition introduces AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, into GSK’s pipeline.

February 17, 2024

CRISPR gene therapy Casgevy secures approval in Europe

Life sciences

Vertex Pharmaceuticals and CRISPR Therapeutics have scored another regulatory approval for Casgevy (exagamglogene autotemcel) after the European Commission granted conditional marketing authorisation to the gene therapy.

February 17, 2024

Gilead to buy liver drugmaker CymaBay for $4.3 Billion

Life sciences

US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50 per share in cash. CymaBay, based in the US near San Francisco, California, has developed the investigational drug seladelpar, which is currently in clinical Phase 3.

How can we help you?

We're easy to reach